Yechun Xu

发表

Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy

Tianliang Li, Haijun Yu, Zhiai Xu, 2021, Acta pharmaceutica Sinica. B.

Identification of C270 as a novel site for allosteric modulators of SARS-CoV-2 papain-like protease

Qiang Shao, H. Su, Guofeng Chen, 2022, bioRxiv.

Structure-based design of a novel inhibitor of the ZIKA virus NS2B/NS3 protease.

H. Su, Fei Cheng, Yi Zou, 2022, Bioorganic chemistry.

In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2

Jian Li, Wenhao Dai, H. Su, 2022, Antiviral Research.

Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.

H. Su, Naixia Zhang, Y. Zhong, 2022, Biochemical pharmacology.

Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase.

Qiu-feng Liu, H. Su, Yin-chun Ji, 2022, Journal of medicinal chemistry.

Flavonoids from the roots and rhizomes of Sophoratonkinensis and their in vitro anti-SARS-CoV-2 activity

Sheng Yao, Hang Xie, H. Su, 2023, Chinese Journal of Natural Medicines.

In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease

Qiang Shao, H. Su, Tianqing Nie, 2022, European Journal of Medicinal Chemistry.

Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19

T. Kronenberger, Hang Xie, S. Pöhlmann, 2023, Pharmaceuticals.

Novel thieno[2,3-b]quinoline-procaine hybrid molecules: A new class of allosteric SHP-1 activators evolved from PTP1B inhibitors

Tingjun Hou, Jia Li, Qianwen Mu, 2022, Chinese Chemical Letters.

Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method

M. Witt, H. Su, C. Ke, 2021, Journal of Pharmaceutical and Biomedical Analysis.

Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay

Qian Zhang, W. Zhang, A. Caflisch, 2022, International Journal of Biological Macromolecules.

Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety

H. Su, Lei-ke Zhang, Xiangrui Jiang, 2023, Bioorganic & medicinal chemistry.

Unraveling the catalytic mechanism of SARS-CoV-2 papain-like protease with allosteric modulation of C270 mutation using multiscale computational approaches

Qiang Shao, H. Su, M. Xiong, 2023, Chemical science.

Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2

H. Su, Lei-ke Zhang, Xiangrui Jiang, 2023, European journal of medicinal chemistry.

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease

H. Su, Guofeng Chen, Jian He, 2023, International journal of molecular sciences.

Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2

Weiliang Zhu, H. Yao, N. Wu, 2023, Signal transduction and targeted therapy.

Structural insights into dimerization and activation of the mGlu2–mGlu3 and mGlu2–mGlu4 heterodimers

Qiang Shao, B. Wu, Shuo Han, 2023, Cell Research.

Spatiotemporal and global profiling of DNA–protein interactions enables discovery of low-affinity transcription factors

Jian Zhang, Ke Yan, Minjia Tan, 2023, Nature Chemistry.

Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2

Lu Liu, Jian Li, Fang Bai, 2023, European Journal of Medicinal Chemistry.

Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group.

Hui Li, Jian Li, Hong Liu, 2023, Journal of medicinal chemistry.

Discovery of novel cGAS inhibitors based on natural flavonoids.

Fengping Zhang, M. Xiong, Yechun Xu, 2023, Bioorganic chemistry (Print).

Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19

J. Qi, Yi Shi, Sheng Yao, 2023, Proceedings of the National Academy of Sciences of the United States of America.

Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial

W. Wang, Lei-ke Zhang, Xiangrui Jiang, 2023, The Lancet regional health. Western Pacific.

Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir

Gengfu Xiao, Yan Zhang, H. Su, 2023, Nature communications.

Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.

H. Su, Xianglei Zhang, Guofeng Chen, 2023, European journal of medicinal chemistry.

Structure-based development of potent and selective type-II kinase inhibitors of RIPK1

Huyan Meng, Xinyu Gong, Yechun Xu, 2023, Acta Pharmaceutica Sinica B.

Multi-omics for COVID-19: driving development of therapeutics and vaccines

Cai-Guang Yang, C. Yi, Chunying Chen, 2023, National science review.

A First-In-Human Phase 1 Study of Simnotrelvir, a 3CL-like Protease Inhibitor for Treatment of COVID-19, in Healthy Adult Subjects.

Lei-ke Zhang, Bufan Yao, Xin-mei Yang, 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Chemical Space Profiling of SARS-CoV-2 PLpro Using DNA-Encoded Focused Libraries.

Xiaojie Lu, Yechun Xu, Hangchen Hu, 2024, ACS medicinal chemistry letters.